Clinical and Pathological Spectrum of Acromegaly: Distinguishing GH PitNETs, Mammosomatotrophs, and Mixed Tumors
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgaf634 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Rebeca Martínez-Hernández und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Nutrition and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER GCV14/ER/12), Hospital Universi…. Hauptthemen laut MEDLINE: Acromegaly, Pituitary Neoplasms, Human Growth Hormone, Neuroendocrine Tumors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Proyectos de Investigacion en Salud, Instituto de Salud Carlos III, European Union.
Abstract (Originalsprache)
Introduction
Acromegaly is a rare disease usually caused by a pituitary neuroendocrine tumor (PitNET) that produces GH PitNET. PitNETs secreting GH and prolactin (GH&PRL PitNETs) contribute up to 30% to the spectrum of acromegaly and have been attributed a more aggressive behavior. GH&PRL PitNETs can be classified into 2 predominant phenotypes: mammosomatotroph arising from a single-cell population of Pit-1 lineage and mixed somatotroph–lactotroph PitNETs (mixed SL PitNETs).
Purpose
To evaluate the clinical and molecular differences between GH PitNETs, mammosomatotroph, and mixed SL PitNETs.
Methods
We quantified GH and PRL expression by double immunofluorescence in 51 PitNETs (23 GH PitNETs, 20 mammosomatotrophs, and 8 mixed SL PitNETs) from patients with acromegaly. These findings were correlated with clinical data and histologic markers such as somatostatin receptor (SSTR)2, SSTR3, SSTR5, E-cadherin, and CAM 5.2.
Results
Our results did not reveal significant differences in GH or IGF-1 levels between GH PitNETs and mixed SL PitNETs, but PRL levels were significantly higher in mammosomatotrophs. Tumor size and invasiveness were comparable between the 2 groups. Interestingly, 41% of prolactin (PRL)-positive tumors did not show hyperprolactinemia, representing silent PRL-positive GH PitNETs. Mixed SL PitNETs exhibited reduced SSTR2 expression, while GH PitNETs exhibited higher SSTR5 levels. Moreover, all tumors lacking cytokeratin expression were nonresponders to medical therapy.
Conclusion
These findings highlight the heterogeneity within GH&PRL PitNETs, including silent PRL-positive GH PitNETs. Our data suggest mixed SL tumors may be less responsive to SSTR ligands, emphasizing the need for tailored strategies based on tumor subtype and receptor profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Nutrition and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER GCV14/ER/12), Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa, U…
- Department of Neurosurgery, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa, Universidad Autónoma de Madrid, 28006 Madrid, Spain.
- Endocrinology & Nutrition Department, Vall d'Hebron University Hospital and Vall d'Hebron Research Institute, Department of Medicine, Autonomous University of Barcelona, Reference Networks (ERN), 08035 Barcelona, Spain.
- Department of Pathology, Hospital Universitario Ramón y Cajal, IRYCIS, CIBERONC, 28034 Madrid, Spain.
- Department of Endocrinology, Hospital Universitario Ramón y Cajal, IRYCIS, CIBERONC, 28034 Madrid, Spain.
- Department of Endocrinology and Nutrition, Germans Trias I Pujol Research Institute and Hospital, Universitat Autònoma de Barcelona, 08916 Badalona, Spain.
ORCID-Profile: Rebeca Martínez-Hernández, Marta Araujo-Castro, Manel Puig-Domingo, Mónica Marazuela
Förderung
- Proyectos de Investigacion en Salud
- Instituto de Salud Carlos III
- European Union
- NextGenerationEU
- iTIRONET
- Comunidad de Madrid
- Sociedad de Endocrinología, Nutrición y Diabetes de la Comunidad de Madrid
- Sociedad Española de Endocrinología y Nutrición
Zitieren
APA
Martínez-Hernández, R., Méndez-García, F. F., Serrano-Somavilla, A., Sacristán-Gómez, P., Sánchez de la Blanca, N., Sampedro-Núñez, M., Navas-Moreno, V., Sebastián-Valles, F., Fernández-Alen, J. A., Biagetti, B., Ruz-Caracuel, I., Araujo-Castro, M., Puig-Domingo, M., & Marazuela, M. (2025). Clinical and Pathological Spectrum of Acromegaly: Distinguishing GH PitNETs, Mammosomatotrophs, and Mixed Tumors. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf634
Vancouver
Martínez-Hernández R, Méndez-García FF, Serrano-Somavilla A, Sacristán-Gómez P, Sánchez de la Blanca N, Sampedro-Núñez M, et al. Clinical and Pathological Spectrum of Acromegaly: Distinguishing GH PitNETs, Mammosomatotrophs, and Mixed Tumors. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgaf634
BibTeX
@article{MartnezHernndez2025,
author = {Martínez-Hernández, Rebeca and Méndez-García, Fernando F and Serrano-Somavilla, Ana and Sacristán-Gómez, Pablo and Sánchez de la Blanca, Nuria and Sampedro-Núñez, Miguel and Navas-Moreno, Víctor and Sebastián-Valles, Fernando and Fernández-Alen, José Antonio and Biagetti, Betina and Ruz-Caracuel, Ignacio and Araujo-Castro, Marta and Puig-Domingo, Manel and Marazuela, Mónica},
title = {Clinical and Pathological Spectrum of Acromegaly: Distinguishing GH PitNETs, Mammosomatotrophs, and Mixed Tumors},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgaf634}
}
EUVIMED